CWP
RARE icon

Concord Wealth Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Concord Wealth Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-12
Closed -$1K – 900
2022
Q2 		$1K Sell
12
-50
-81% -$3.08K ﹤0.01% 1181
2022
Q1 		$5K Hold
62
– – ﹤0.01% 919
2021
Q4 		$5K Buy
62
+50
+417% +$4.07K ﹤0.01% 959
2021
Q3 		$1K Hold
12
– – ﹤0.01% 859
2021
Q2 		$1K Hold
12
– – ﹤0.01% 1000
2021
Q1 		$1K Hold
12
– – ﹤0.01% 944
2020
Q4 		$2K Buy
+12
New +$1.42K ﹤0.01% 560

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Concord Wealth Partners's RARE Position: Q3 2022 in Review

Concord Wealth Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2022, closing a stake of 12 shares — an estimated $1K sold.

Concord Wealth Partners first reported a position in RARE in Q4 2020 and held it in 7 quarters. The position peaked at $5K in Q1 2022. 232 funds tracked by Wall St. Rank hold RARE as of Q3 2022.

  • Concord Wealth Partners reported no remaining Ultragenyx Pharmaceutical position as of Q3 2022 after selling out during the quarter.
  • Concord Wealth Partners sold 12 Ultragenyx Pharmaceutical shares in Q3 2022, an estimated $1K.
  • Concord Wealth Partners first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and held it in 7 quarters.
  • Concord Wealth Partners's Ultragenyx Pharmaceutical position peaked at $5K in Q1 2022.
  • 232 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2022.

Based on Concord Wealth Partners's 13F filing for Q3 2022, filed 10 Nov 2022.